• Home
• People
• Bio
• Melanie Beaton

Melanie Beaton

Melanie Beaton completed her MD at the University of Ottawa and residency training in Internal Medicine and Gastroenterology at Western University. She subsequently completed a research fellowship at the Queensland Institute of Medical Research and Royal Brisbane Hospital in Brisbane, Australia. After returning to London she joined the Department of Medicine in the Division of Gastroenterology at Western University. Her clinical practice encompasses general gastroenterology with a focus in the management of Inflammatory Bowel Disease (IBD) and Nonalcoholic Fatty Liver Disease (NAFLD). She is actively involved in Clinical Trials and investigator-initiated research in both of these areas. She is the Site Chief of University Hospital for Gastroenterology, as well as, the Equity and Wellness Lead for the Division and its trainees.

Selected Publications

Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype. Choi B, Sey M, Ponich T, Beaton M, Kim R, Wilson A. Inflamm Bowel Dis. 2022 Sep 16:izac188. doi: 10.1093/ibd/izac188. Online ahead of print. PMID: 36112504

Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center. Sedano R, Guizzetti L, McDonald C, Beaton M, Chande N, Gregor J, Sey M, Wilson A, Jairath V. Inflamm Bowel Dis. 2022 Jul 19:izac149. doi: 10.1093/ibd/izac149. Online ahead of print. PMID: 35851799

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R, Sey M, Beaton M, Yan B, Kim RB, Wilson A. Sci Rep. 2022 Jan 24;12(1):1185. doi: 10.1038/s41598-022-05208-9. PMID: 35075155

Wilson A, Wang Q, Choi YH, Ponich T, Gregor JC, Chande N, Yan B, Sey M, Beaton M, Kim RB. Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. Clin Transl Gastroenterol. 2021 Apr, Coauthor, DOI: doi: 10.14309/ctg.0000000000000332.

Wilson A, Choi B, Sey M, Ponich T, Beaton M, Kim RB. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study. BMC Gastroenterol, 2021 Feb 18; 21 (1): 77, Coauthor, DOI: 10.1186/s12876-021-01650-7.

Mahmud FH, Clarke ABM, Joachim KC, Assor E, McDonald C, Saibil F, Lochnan HA, Punthakee Z, Parikh A, Advani A, Shah BR, Perkins BA, Zuijdwijk CS, Mack DR, Koltin D, De Melo EN, Hsieh E, Mukerji G, Gilbert J, Bax K, Lawson ML, Cino M, Beaton MD, Saloojee NA, Lou O, Gallego PH, Bercik P, Houlden RL, Aronson R, Kirsch SE, Paterson WG, Marcon MA. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Diabetes Care, 2020 Jul 1; 43(7): 1553-1556, Coauthor, DOI: Available from: https://doi: 10.2337/dc19-1944.

Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, McKenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol, 2020 Jul; 115(7) (1055-1065), Coauthor, DOI: doi: 10.14309/ajg.0000000000000661.

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 May; 26(6) (949-959), Coauthor

Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB. Crohn’s Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Mol Pharm, 2019 Sep; 16(9) (4059-4064), Coauthor, DOI: doi: 10.1021/acs.molpharmaceut.9b00459. Epub 2019 Aug 19.

Perera S, Bistritz L, Beaton MD. Equity and Gender Issues Among Members of the Canadian Association of Gastroenterology. Journal of the Canadian Association of Gastroenterology, 2018 Aug 28; https://doi.org/10.1, Coauthor

Tirona RG, Kassam Z, Strapp R, Ramu M, Zhu C, Liu M, Schwarz UI, Kim RB, Al-Judaibi B, Beaton MD. Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metaoblism and Disposition, 2018 Feb 22; dmd.117.079624, Senior Responsible Author

Wilson AS, Jansen L, Rose R, Gregor J, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft W, Kim R. HLA-DQA1-HLA-DRB1 Polymorphism is a Major Predictor of Azathioprine-induced Pancreatitis in Patients with Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 2017 Dec 22, Coauthor

Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Mahlhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohapatitis: A randomized, placebo-controlled trial. World J Gastroenterol, 2017 Jan 7; 23 (1): 141-150, Coauthor

Woolsey SJ, Beaton MD, Mansell SE, Leon-Ponte M, Yu J, Pin CL, Adams PC, Kim RB, Tirona RG. A Fibroblast Growth Factor 21 - Pregnane X Receptor Pathway Downregulates Hepatic Cytochrome P450 3A4 in Nonalcoholic Fatty Liver Disease. Mol Pharmacol, 2016 Aug 1; pii:mol.116.104687, Coauthor

Beaton MD, Al-Judaibi B. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016? Saudi J Gastroenterol, 2016 May 1; 22 (3): 169-70, Principal Author, DOI: 10.4103/1319-3767.182462.

Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, Tirona RG. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. Basic Clin Pharmacol Toxicol, 2016 Apr 1; 118 (4): 284-91, Coauthor, DOI: 10.1111/bcpt.12492.

Wells MM, Li Z, Addeman B, McKenzie CA, Mujoomdar A, Beaton M, Bird J. Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. Can J Gastroenterol Hepatol, 2016 Jan 1; 2016: 4930987, Coauthor, DOI: 10.1155/2016/4930987.